Finding Bone Risk in a Ten-Minute Consultation | NICE NG259 Framework

The Soulful GP Clinical Lens By Dr Rabia | Clinical evidence checked: 25 September 2026

A practical primary-care framework for menopause, inflammation, steroid exposure and fracture prevention

NICE framework: NG259, Osteoporosis: risk assessment (published 29 July 2026; replaces CG146).

For healthcare professionals: This article is an educational prompt, not a substitute for current NICE guidance, NOGG, specialist advice, medicines guidance, or local pathways. It reflects published NICE NG259, rather than earlier consultation documents; check the current guideline and local referral/treatment criteria before making clinical decisions.

A 53-year-old patient says, “My joints have been aching since my periods became irregular.”

She has rheumatoid arthritis, has needed several courses of prednisolone over the last year, has become less active because of pain, and tells you her mother fractured a hip in her seventies.

It would be easy to contain this consultation inside one familiar box: menopause. Or inflammatory arthritis. Or pain.

The safer move is to notice that the boxes overlap.

The task is not to diagnose osteoporosis in ten minutes. It is to identify a person whose fracture risk needs active assessment, explain why, and agree the next step without making them feel reduced to age, weight, or a scan result.

This matters because the current published NICE guideline, NG259: Osteoporosis—risk assessment, was published on 29 July 2026. It replaces CG146 and makes the case-finding logic much clearer.⁵

The clinical principle: do not wait for a fracture to make risk visible

Osteoporosis is often discovered after a fragility fracture. That is a failure of visibility, not of patient motivation. Risk accumulates across menopause, inflammatory disease, glucocorticoid exposure, previous fracture, falls, family history, low body mass, smoking, alcohol, malabsorption, immobility, and medicines.

For patients with inflammatory rheumatic and musculoskeletal disease, the causal story is more complex than the shorthand “steroids cause osteoporosis.” A 2024 review describes the contribution of systemic and local inflammation, disability, malnutrition, hormonal loss, glucocorticoids, and general fracture-risk factors. It argues for a multimodal approach: control inflammation, minimise glucocorticoid exposure where clinically possible, address nutrition and physical activity, prevent falls, and use bone-specific treatment when indicated.⁹

In other words: arthralgia and bone risk are not competing diagnoses. A menopause consultation and a fracture-risk assessment can belong in the same encounter.

A ten-minute framework: notice, assess, act, safety-net

Minutes 0–2: Make the agenda broader than the symptom

Start with the symptom the patient has brought. Then say why you are widening the frame.

“The joint symptoms matter in their own right. Because menopause, inflammation and some steroid exposure can also affect bone strength, I would like to check whether your future fracture risk is something we should assess as well.”

This language avoids the two common errors: implying that the symptom is “only menopause”, or creating unnecessary alarm by presenting a risk check as a diagnosis.

Be careful with shorthand. Menopause-associated musculoskeletal symptoms are recognised in NICE NG23, but they should not automatically close the differential. NICE also advises discussing bone health at menopause reviews and encouraging activity that maintains muscle mass and strength.²

Minutes 2–4: Find the risk triggers

A focused screen is usually enough to decide whether to proceed to formal assessment or organise follow-up. Ask about:

Domain	High-yield prompts
Fracture and falls	Previous fracture after a fall from standing height or less; height loss; new thoracic/lumbar pain; change in posture; two or more falls in the previous year.
Hormonal history	Menopause status; untreated early menopause or premature ovarian insufficiency; oophorectomy; endocrine causes of hypogonadism; cancer treatments that affect hormones.
Inflammation and medicines	Rheumatoid arthritis, lupus, spondyloarthritis, inflammatory bowel disease, coeliac disease; current, repeated or previous systemic glucocorticoids; other medicines associated with fracture risk.
Family and lifestyle	First-degree relative with hip fracture; low BMI; smoking; alcohol above 14 units/week; prolonged immobility; nutrition and falls concerns.

NG259 recommends risk assessment in all people aged 50 and over, and in women who have experienced menopause, if there has been a previous fragility fracture or current/frequent systemic glucocorticoid use. It also advises considering assessment in all women aged 65 and over, all men aged 75 and over, and younger people with the risk factors above. Rheumatoid arthritis, other inflammatory arthropathies, coeliac disease, inflammatory bowel disease, chronic kidney disease stage 4 and 5, low BMI, falls, and a first-degree relative with hip fracture are all explicitly recognised risk factors.⁵

Do not over-rely on visual stereotypes. A patient does not need to be elderly, White, very thin, or visibly frail for risk assessment to be appropriate. Use the tool as an aid to judgement, not as a replacement for it.

Minutes 4–6: Turn risk factors into a plan for assessment

Explain the next step in plain language.

“A scan may be part of this, but the first step is a fracture-risk assessment. It looks at the whole picture: your fracture history, menopause, medicines, health conditions and falls risk. That tells us whether a bone-density scan or treatment discussion is needed.”

Use the current validated risk tool and local pathway. NICE supports the use of fracture-risk assessment tools, and NOGG recommends FRAX assessment in postmenopausal women and men aged 50 or over with a clinical risk factor.⁵ ⁷

NG259 is more specific about the pathway. Complete a full clinical risk assessment alongside either FRAX or QFracture for people aged 40–90, and alongside QFracture for people aged 30–39. Use the same tool throughout a person’s care. For people under 30, or where a rare bone disease is suspected, seek specialist advice.⁵

Remember that FRAX and QFracture are not interchangeable. Their outputs differ, and NOGG intervention thresholds are based on FRAX probability. Clinical judgement remains necessary where risk exceeds what a calculator can capture, including high-dose glucocorticoids, falls, and discordant lumbar-spine bone density.⁷

Risk prediction should usually inform selective DXA use, but it is not an administrative hurdle. NG259 says to offer DXA, with or without first completing a risk-prediction tool, to people aged 30 and over with a previous hip or vertebral fragility fracture, a single major osteoporotic fragility fracture within the past two years, or two or more fragility fractures. It also says to consider DXA to guide treatment decisions when the 10-year major-osteoporotic-fracture risk is 10% or more.⁵

DXA should be used to answer a clinical question, not as a generic reassurance test. NG259 also recommends baseline DXA when starting treatment unless it is not tolerated, technically feasible, or not needed for treatment or monitoring decisions. A “normal” or non-osteoporotic DXA result does not erase falls risk, steroid exposure, inflammatory disease, or a fragility fracture.⁵

Minutes 6–8: Do not miss the steroid prompt

Current or frequent systemic glucocorticoids should trigger a deliberate review, not an incidental note in the medication list. NICE gives the example of prednisolone 5 mg daily or equivalent for over three months, or intermittent higher doses, as a risk factor that merits fracture-risk assessment in relevant age/menopause groups.⁵

NOGG goes further for glucocorticoid-induced osteoporosis: because bone loss and fracture risk can occur early, it recommends starting bone-protective treatment alongside glucocorticoid therapy, without waiting for bone-density assessment, for specified higher-risk groups. These include people with a prior fragility fracture, women aged 70 or over, postmenopausal women and men aged 50 or over receiving high-dose glucocorticoids, and those whose FRAX probability exceeds the intervention threshold.⁸

The clinical action is not “prescribe automatically from a blog.” It is to recognise the time-sensitive risk, consult the current NOGG/local treatment pathway, consider contraindications and renal function, and arrange timely follow-up rather than leaving the issue until the next annual review.

A useful EHR prompt could read:

Bone risk review: previous fragility fracture? menopause/POI? systemic steroid dose, duration and cumulative courses? inflammatory disease? falls? first-degree hip fracture? BMI? smoking/alcohol? FRAX/local pathway action documented?

Minutes 8–10: Offer preventive action without lifestyle moralising

The patient does not need another message that they should simply “move more” and “eat better.” They need an achievable plan matched to pain, fatigue, function, financial access, culture, and safety.

NOGG recommends a nutrient-rich balanced diet, at least 700 mg calcium daily preferably from food, vitamin D management when deficiency or risk factors are present, and regular weight-bearing plus muscle-strengthening exercise tailored to the person. It also recommends falls assessment for people with osteoporosis or fragility fracture, smoking cessation, and limiting alcohol to no more than two units a day.³

Offer movement as rehabilitation and confidence-building, not as a test of virtue. The evidence supports it, but it needs nuance. A 2025 systematic review and meta-analysis found resistance training improved bone density at several skeletal sites in postmenopausal women; however, substantial heterogeneity means that exact prescriptions should not be copied uncritically into every consultation.⁴

For a patient with active inflammatory disease, recurrent falls, vertebral fracture, or significant fear of movement, a physiotherapy referral or specialist-supported plan may be more useful than generic gym advice.

Do not miss the quiet vertebral fracture

Ask about loss of height, kyphosis, unexplained back or radiating rib pain, and a sudden change in function. Vertebral fractures can be missed because they may not present as a dramatic trauma.

The new NICE guideline advises considering a DXA-based vertebral fracture assessment (VFA) when a DXA scan is being performed for women aged 60 and over or men aged 70 and over. For younger people, it advises considering VFA when there are risk indicators such as a prior major osteoporotic fracture, symptoms/signs suggestive of vertebral fracture, current/frequent systemic glucocorticoid use, or exceptionally low BMD for age.⁶

This is an opportunity to move beyond “back pain equals musculoskeletal reassurance” when the wider risk story suggests otherwise.

The equity question: who is not being asked?

The patient who presents with fatigue, joint pain, a complicated medicine list, multiple caring responsibilities, or limited English may not volunteer fracture risk. Menopause can be missed in people who do not identify with the usual public narrative. Steroid courses may be scattered across urgent-care records. Inflammatory disease may dominate a consultation so completely that prevention disappears.

NICE explicitly asks for individualised assessment for trans and non-binary people, taking account of sex registered at birth, hormonal history and current hormone treatment where relevant.⁵ NOGG also cautions that clinical judgement is needed beyond calculator fields and explains limitations around tool calibration.⁷

The most equitable question may simply be: “Has anyone ever talked to you about how your condition or medicines could affect your bone strength?”

A one-minute close that patients can remember

“We have identified a few factors that can raise fracture risk. That does not mean you have osteoporosis. It means your bones deserve a proper assessment. I am going to [complete a risk assessment / arrange follow-up / request DXA according to pathway / seek specialist advice], and we will also make a plan that supports your strength and reduces falls risk.”

That is clinically honest. It is emotionally containing. And it moves bone health from an incidental possibility to a shared preventive plan.

Key takeaways

The purpose of the short consultation is case finding, not an instant osteoporosis diagnosis.
Menopause, inflammatory disease and glucocorticoid exposure often overlap; do not force the patient into one explanatory box.
Use NG259, a validated risk tool, NOGG, and local pathways; tools inform judgement but do not replace it.
Treat glucocorticoid exposure as time-sensitive. Do not wait for a fracture or a delayed DXA result when guideline criteria for action are met.
Make prevention practical: tailored strength and weight-bearing activity, nutrition, vitamin D/calcium assessment where appropriate, inflammation control, falls prevention, and medication review.

Clinical FAQs

Does menopause alone mean that a patient needs a DXA scan?

Not routinely. Use menopause as an opportunity to ask about bone health and formalise the wider risk history. Under NG259, assessment is particularly indicated in people aged 50 and over and women who have experienced menopause with a prior fragility fracture or current/frequent systemic glucocorticoid exposure; additional risk factors guide case finding and the decision to use DXA.² ⁵

Which risk tool should I use: FRAX or QFracture?

Use the validated tool supported by the current local pathway, and understand what it reports. Under NG259, complete a full clinical risk assessment alongside FRAX or QFracture for people aged 40–90, and alongside QFracture for people aged 30–39; use the same tool throughout their care. NOGG recommends FRAX for postmenopausal women and men aged 50 or over with a clinical risk factor. FRAX and QFracture are not interchangeable, and NOGG intervention thresholds are based on FRAX probability.⁵ ⁷

When can DXA proceed without first completing a risk-prediction tool?

For people aged 30 or over with a previous hip or vertebral fragility fracture, one major osteoporotic fragility fracture in the past two years, or two or more fragility fractures, NG259 says to offer DXA with or without first completing a risk-prediction tool. In other cases, use the full clinical assessment and risk-prediction pathway to guide selective DXA use and treatment decisions.⁵

Does rheumatoid arthritis itself count as a fracture-risk factor?

Yes. NG259 explicitly includes rheumatoid arthritis and other inflammatory arthropathies among conditions associated with increased fragility-fracture risk. The consultation should also consider disease activity, function, falls, nutrition, menopause, and glucocorticoid exposure rather than attributing risk to a single factor.⁵ ⁹

How should I think about intermittent steroid bursts?

Do not treat repeated rescue courses as invisible exposure. NG259 includes intermittent higher-dose systemic glucocorticoids in its risk-assessment criteria. Record dose, duration, timing, cumulative pattern and indication, then apply clinical judgement, FRAX where appropriate, NOGG, and the local pathway. If risk is high, do not defer action solely because a DXA scan is pending.⁵ ⁷ ⁸

When should I consider vertebral fracture assessment with DXA?

NG259 advises considering DXA-based VFA for women aged 60 or over and men aged 70 or over who are having a DXA scan. In younger people having DXA, consider it when there is a prior major osteoporotic fracture, symptoms or signs suggestive of vertebral fracture, current/frequent systemic glucocorticoid use, or exceptionally low BMD for age.⁶

Looking for the patient-facing version? Read Bone Health Before the Fracture.